Drug Profile
EV 102
Alternative Names: EV-102Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Enveric Biosciences
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Radiodermatitis
Most Recent Events
- 18 Nov 2021 Pharmacodynamics data from preclinical studies in Radiodermatitis released by Enveric Biosciences
- 18 Nov 2021 Enveric Biosciences plans phase I/II trial for EV 102 in the second half of 2022
- 30 Aug 2021 EV 102 is available for licensing as of 30 Aug 2021. https://www.enveric.com/contact/partnership-inquiries/